Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than ...

Moderna (NASDAQ:MRNA) shares fell ~5% in the premarket on Friday after the COVID-19 vaccine maker, with its Q4 2024 results, topped the consensus for revenue but missed Street forecasts for ...

Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Welcome to the Moderna Fourth Quarter 2024 Conference Call ... excluding the resizing charge this would have been 53%. R&D expenses in Q4 were $1.1 billion, reflecting a 20% year-over-year ...